Daiichi Life Insurance Co. Ltd. Buys Shares of 36,343 Boston Scientific Corporation $BSX

Daiichi Life Insurance Co. Ltd. purchased a new stake in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 36,343 shares of the medical equipment provider's stock, valued at approximately $1,551,000.

Several other institutional investors and hedge funds have also recently made changes to their positions in BSX. Brighton Jones LLC raised its stake in Boston Scientific by 0.8% in the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider's stock valued at $2,445,000 after buying an additional 226 shares during the last quarter. FWL Investment Management LLC purchased a new stake in shares of Boston Scientific during the second quarter valued at $26,000. Main Street Financial Solutions LLC increased its position in shares of Boston Scientific by 35.3% in the 2nd quarter. Main Street Financial Solutions LLC now owns 7,556 shares of the medical equipment provider's stock valued at $812,000 after acquiring an additional 1,971 shares during the period. Ieq Capital LLC increased its position in shares of Boston Scientific by 97.0% in the 2nd quarter. Ieq Capital LLC now owns 123,592 shares of the medical equipment provider's stock valued at $13,275,000 after acquiring an additional 60,860 shares during the period. Finally, HUB Investment Partners LLC grew its stake in Boston Scientific by 56.2% during the 2nd quarter. HUB Investment Partners LLC now owns 7,102 shares of the medical equipment provider's stock valued at $763,000 after purchasing an additional 2,556 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on BSX shares. Wolfe Research lowered Boston Scientific from an "outperform" rating to a "peer perform" rating in a research report on Friday, May 29th. BTIG Research dropped their price objective on shares of Boston Scientific from $65.00 to $60.00 and set a "buy" rating on the stock in a report on Wednesday, July 29th. Royal Bank Of Canada lowered their price target on shares of Boston Scientific from $85.00 to $70.00 and set an "outperform" rating on the stock in a report on Thursday, July 30th. Wall Street Zen cut Boston Scientific from a "buy" rating to a "hold" rating in a report on Sunday, August 2nd. Finally, UBS Group lowered their target price on Boston Scientific from $74.00 to $67.00 and set a "buy" rating on the stock in a research note on Thursday, July 30th. Twenty-four equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $71.62.

Insider Activity

In related news, Director Edward J. Ludwig acquired 5,000 shares of the firm's stock in a transaction on Friday, July 31st. The shares were acquired at an average cost of $45.48 per share, with a total value of $227,400.00. Following the completion of the acquisition, the director directly owned 30,359 shares in the company, valued at approximately $1,380,727.32. This trade represents a 19.72% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Michael F. Mahoney bought 186,240 shares of the business's stock in a transaction dated Monday, August 3rd. The shares were bought at an average cost of $48.33 per share, with a total value of $9,000,979.20. Following the purchase, the chief executive officer directly owned 1,590,024 shares of the company's stock, valued at approximately $76,845,859.92. This represents a 13.27% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have acquired 194,522 shares of company stock worth $9,385,210 in the last quarter. Corporate insiders own 0.34% of the company's stock.

Boston Scientific Stock Up 0.0%

BSX opened at $50.39 on Monday. Boston Scientific Corporation has a fifty-two week low of $42.20 and a fifty-two week high of $109.50. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24. The company has a fifty day moving average of $46.34 and a two-hundred day moving average of $57.62. The stock has a market capitalization of $73.03 billion, a price-to-earnings ratio of 20.40, a PEG ratio of 1.10 and a beta of 0.56.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping analysts' consensus estimates of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The business had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. During the same quarter in the prior year, the firm posted $0.75 earnings per share. The company's revenue was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, research analysts expect that Boston Scientific Corporation will post 3.3 earnings per share for the current year.

Boston Scientific declared that its Board of Directors has approved a share repurchase plan on Monday, May 18th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the medical equipment provider to buy up to 6.4% of its shares through open market purchases. Shares buyback plans are usually a sign that the company's board of directors believes its shares are undervalued.

Boston Scientific Profile

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source